Targeted Triple Inhibition of KRAS, EGFR, and STAT3 in Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by near-universal activating mutations in KRAS and frequent co-mutations in TP53, CDKN2A, and SMAD4. Despite advances in targeted therapy, single-agent inhibition of KRAS has demonstrated limited durability due to rapid emergence of adaptive resistance mechanisms.
This lecture reviews a recent preclinical study demonstrating that simultaneous pharmacologic inhibition of three critical signaling nodes—KRAS, EGFR, and STAT3—induces complete and durable tumor regression in murine models of PDAC, including orthotopic and patient-derived xenograft (PDX) systems.
By the end of this lecture, participants will be able to:
* Explain why KRAS-mutant PDAC demonstrates rapid resistance to single-agent KRAS inhibition.
* Describe the role of EGFR and STAT3 in adaptive signaling escape.
* Discuss this study curing PDX in mice by blocking STAT3 protein clusters.
* Evaluate the strengths and limitations of preclinical combination therapy studies.
By the end of this lecture, participants will be able to:
* Explain why KRAS-mutant PDAC demonstrates rapid resistance to single-agent KRAS inhibition.
* Describe the role of EGFR and STAT3 in adaptive signaling escape.
* Discuss this study curing PDX in mice by blocking STAT3 protein clusters.
* Evaluate the strengths and limitations of preclinical combination therapy studies.
Faculty
In addition to the presenter, following authors may have helped with the content writing, review,
or approval:
CME, CE, CEU and Other Credit Types:
ACCME Accreditation Statement
The DrBeen Corp is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
AMA Credit Designation Statement
The DrBeen Corp designates this enduring material for a maximum of 0.75 AMA PRA Category 1
Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the
activity.
Disclosure Information
In accordance with the disclosure policies of DrBeen Corp and the ACCME (Accreditation Council for
Continuing Medical Education), we are committed to upholding principles of balance, independence,
objectivity, and scientific rigor in all of our Continuing Medical Education (CME) and Continuing
Education (CE) activities. These policies include the careful management and mitigation of any relevant
financial relationships with organizations that are not eligible.
All members of the Activity Planning Committee and presenters have disclosed their relevant financial
relationships. The DrBeen Corp CE Committee has thoroughly reviewed these disclosures and determined
that these relationships are not deemed inappropriate in the context of their respective presentations.
Additionally, they are found to be consistent with the educational objectives and the integrity of the
activity.
| Faculty |
Disclosures |
|
Author declares no conflict of interest. |
Write A New Comment
2 Comments
naturalhealthworks@*.com
May 04 2026, 3:46 pm
Is there a phone number for my patient to converse with you?
naturalhealthworks@*.com
May 04 2026, 3:44 pm
physician in the great State of Florida. I have a patient who has pancreatic and liver cancer. Regular western medicine offers no hope. They have put him on pain meds. he has come to me for help. I was wondering